CHMP backs Glybera for LPL deficiency
12:33 EDT 20 Jul 2012 | BioCentury
EMA's CHMP recommended approval of an MAA from uniQure B.V. (Amsterdam, the Netherlands) for Glybera alipogene tipavovec to treat lipoprotein lipase (LPL) deficiency in patients with severe or multiple pancreatitis attacks, despite dietary fat restri..
Original Article: CHMP backs Glybera for LPL deficiency
More From BioPortfolio on "CHMP backs Glybera for LPL deficiency"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
